首页|组蛋白甲基转移酶2抑制剂BAY-598和阿霉素在骨肉瘤中的协同抗癌作用

组蛋白甲基转移酶2抑制剂BAY-598和阿霉素在骨肉瘤中的协同抗癌作用

扫码查看
目的 探讨组蛋白的甲基转移酶2抑制剂BAY-598和阿霉素在骨肉瘤中的协同抗癌作用.方法 通过细胞的增殖、迁移、侵袭和集落形成实验,评估两种药物单独或联合使用后对骨肉瘤细胞恶性特征的抑制作用.采用流式细胞术检测细胞凋亡和细胞周期情况.结果 组蛋白甲基转移酶2抑制剂和阿霉素联合治疗可协同抑制细胞的生长、迁移、侵袭,诱导细胞凋亡,导致OS细胞细胞周期阻滞.进一步的机制探索表明,JAK-STAT信号通路可能是协同作用的关键.结论 组蛋白甲基转移酶2抑制剂和阿霉素对骨肉瘤具有协同抗癌作用,它们的联合使用可能是一种很有前途的骨肉瘤治疗策略.
The Synergistic Anticancer Effect of Histone Methyl transferase 2 Inhibitor BAY-598 and Doxorubicin in Osteosarcoma
Objective To investigate the synergistic anticancer effect of BAY-598,a histone methyltransferase 2 inhibi-tor,and doxorubicin in osteosarcoma.Methods The inhibitory effects of the 2 drugs,either alone or in combination,on the malig-nant characteristics of osteosarcoma cells were assessed through experiments involving cell proliferation,migration,invasion,and colony formation.Flow cytometry was employed to detect cell apoptosis and the cell cycle.Results Combined treatment with his-tone methyltransferase 2 inhibitors and doxorubicin synergistically inhibited cell growth,migration,and invasion,inducing cell ap-optosis and leading to cell cycle arrest in osteosarcoma cells.Further mechanistic exploration suggested that the JAK-STAT signa-ling pathway might be a key player in this synergistic effect.Conclusion Histone methyltransferase 2 inhibitors and doxorubicin have synergistic anticancer effects on osteosarcoma,and their combined use may be a promising treatment strategy for osteosarco-ma.

DoxorubicinHistone methyltransferase 2 inhibitorOsteosarcomaSynergy

蔡风、陶绪长、刘鲁华、熊晒、黎腾、刘浪、曾铎、廖琦

展开 >

330006 江西省南昌市第一医院

330006 江西嘉佑曙光骨科医院

阿霉素 组蛋白甲基转移酶2抑制剂 骨肉瘤 协同作用

江西省教育厅科学技术研究项目

GJJ190104

2024

实用癌症杂志
江西省肿瘤医院 江西省肿瘤研究所

实用癌症杂志

影响因子:1.241
ISSN:1001-5930
年,卷(期):2024.39(10)